Steven Cohen Bicycle Therapeutics PLC Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 58,500 shares of BCYC stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,500
Previous 58,500
-0.0%
Holding current value
$1.36 Million
Previous $1.18 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BCYC
# of Institutions
111Shares Held
40.7MCall Options Held
3.4KPut Options Held
12.4K-
Baker Bros. Advisors LP New York, NY9.4MShares$218 Million2.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$81 Million2.32% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$52.3 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.12MShares$49.3 Million6.34% of portfolio
-
Armistice Capital, LLC New York, NY1.97MShares$45.8 Million0.52% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $689M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...